Literature DB >> 2013808

The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.

J Okada1, K Yoshikawa, K Imazeki, S Minoshima, K Uno, J Itami, J Kuyama, H Maruno, N Arimizu.   

Abstract

Twenty-one patients with untreated malignant lymphoma in the head and neck region were evaluated with positron emission tomography (PET) using fluorine-18-fluorodeoxyglucose (FDG) and gallium-67 SPECT imaging. Tumor-to-normal soft-tissue contrast ratios (TCRs) obtained 60 min after injection of FDG were higher than 2.6, and all malignant lymphomas were clearly visualized. In patients with poor prognosis, higher TCRs and glucose utilization rates (GURs) were observed, whereas low TCR and GUR were shown in a patient with low-grade malignancy. In comparison with 67Ga scintigraphy, patients with high TCRs and GURs were likely to show increased accumulation of gallium-67, but accumulation of gallium-67 was not increased as much as FDG in poor prognostic patients. FDG-PET may be useful in the detection and management of malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013808

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.

Authors:  Joerg Theisen; Bernd Krause; Christian Peschel; Roland Schmid; Hans Geinitz; Helmut Friess
Journal:  World J Gastrointest Surg       Date:  2009-11-30

2.  Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.

Authors:  T Miyauchi; R L Wahl
Journal:  Eur J Nucl Med       Date:  1996-05

3.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 4.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

5.  Does leukocyte scintigraphy answer the need for a more widely available radiopharmaceutical that can detect and assess the proliferative state of lymphoma?

Authors:  C Van de Wiele; M Simons; L Noens; R A Dierckx
Journal:  Eur J Nucl Med       Date:  1996-04

6.  Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity.

Authors:  K Ito; T Kato; T Ohta; M Tadokoro; T Yamada; M Ikeda; M Nishino; T Ishigaki; S Gambhir
Journal:  Eur J Nucl Med       Date:  1996-10

7.  Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; H Goldschmidt; W J Lorenz; W Maier-Borst; G van Kaick
Journal:  Eur J Nucl Med       Date:  1995-05

8.  Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.

Authors:  Katja Ott; Wolfgang A Weber; Ulrich Fink; Hermann Helmberger; Karen Becker; Hubert J Stein; James Müller; Markus Schwaiger; Jörg Rüdiger Siewert
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

9.  Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

Authors:  Pierre Y Salaun; Thomas Gastinne; Caroline Bodet-Milin; Loïc Campion; Pierre Cambefort; Anne Moreau; Steven Le Gouill; Christian Berthou; Philippe Moreau; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-05       Impact factor: 9.236

10.  Fluorodeoxyglucose cell incorporation as an index of cell proliferation: evaluation of accuracy in cell culture.

Authors:  D O Slosman; N Pittet; A Donath; B S Polla
Journal:  Eur J Nucl Med       Date:  1993-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.